296 related articles for article (PubMed ID: 27239883)
1. The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mintzes B
Int J Health Policy Manag; 2016 Feb; 5(5):329-31. PubMed ID: 27239883
[TBL] [Abstract][Full Text] [Related]
2. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better? Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Doran E
Int J Health Policy Manag; 2016 Feb; 5(5):333-5. PubMed ID: 27239884
[TBL] [Abstract][Full Text] [Related]
3. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
4. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Mackey TK
Int J Health Policy Manag; 2016 Feb; 5(4):271-4. PubMed ID: 27239871
[TBL] [Abstract][Full Text] [Related]
5. Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Rollins BL
Int J Health Policy Manag; 2016 Feb; 5(4):287-8. PubMed ID: 27239875
[TBL] [Abstract][Full Text] [Related]
6. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Wanasika I
Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
[TBL] [Abstract][Full Text] [Related]
7. Considering the Future of Pharmaceutical Promotions in Social Media Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Carpentier FR
Int J Health Policy Manag; 2016 Feb; 5(4):283-5. PubMed ID: 27239874
[TBL] [Abstract][Full Text] [Related]
8. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
9. Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.
Kannan S; Gowri S; Tyagi V; Kohli S; Jain R; Kapil P; Bhardwaj A
Int J Risk Saf Med; 2015; 27(2):77-83. PubMed ID: 26410010
[TBL] [Abstract][Full Text] [Related]
10. Can direct-to-consumer advertising of prescription drugs be effectively regulated?
Lexchin J; Menkes DB
N Z Med J; 2019 Jun; 132(1496):59-65. PubMed ID: 31170134
[TBL] [Abstract][Full Text] [Related]
11. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
Adams C
J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
[TBL] [Abstract][Full Text] [Related]
12. Future Challenges and Opportunities in Online Prescription Drug Promotion Research Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Southwell BG; Rupert DJ
Int J Health Policy Manag; 2016 Jan; 5(3):211-3. PubMed ID: 26927597
[TBL] [Abstract][Full Text] [Related]
13. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.
Klara K; Kim J; Ross JS
J Gen Intern Med; 2018 May; 33(5):651-658. PubMed ID: 29484575
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
Tyrawski J; DeAndrea DC
J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
[TBL] [Abstract][Full Text] [Related]
15. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
[TBL] [Abstract][Full Text] [Related]
16. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
Bradford WD; Kleit AN
Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
[TBL] [Abstract][Full Text] [Related]
17. Trends in direct-to-consumer advertising of prescription contraceptives.
Wu MH; Bartz D; Avorn J; Seeger JD
Contraception; 2016 May; 93(5):398-405. PubMed ID: 26808088
[TBL] [Abstract][Full Text] [Related]
18. A survey of perceptions and attitudes about direct-to-consumer advertising of prescription drugs among college students in South Korea.
Yang YM; Lee JJ; Jeong E; Kim SY; Han MA; Choi EJ
PLoS One; 2018; 13(7):e0201108. PubMed ID: 30040833
[TBL] [Abstract][Full Text] [Related]
19. Problems associated with direct-to-consumer advertising (DTCA) of restricted, implantable medical devices: should the current regulatory approach be changed?
Patsner B
Food Drug Law J; 2009; 64(1):1-41. PubMed ID: 19998571
[TBL] [Abstract][Full Text] [Related]
20. Effects of conflicting prescription drug information from direct-to-consumer advertising and drug injury advertising on patients' beliefs and medication adherence.
Im H; Huh J
Res Social Adm Pharm; 2022 Jul; 18(7):3119-3130. PubMed ID: 34454872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
